RE: Mass testing StrepA9 Dec 2022 19:05
http://novacyt.com/wp-content/uploads/2021/09/Investor-meeting-QA-August-2021-ENG.pdf
Here is what DA had to say in August, Investor question 7 is relevant.
7. What about your business outside of molecular diagnostics? What progress is being made
with LFTs? How much revenue do you have from LFT? How do you expect LFTs to fit within
future COVID testing, what percentage are they likely to make up of sales mix and do you
think the technology will receive more attention in the future?
Ans 7: In the last few months, we’ve launched LFT tests for both COVID antigen and COVID antibody detection and
these tests have been launched for professional use. We’ve also submitted data to regulatory authorities for
patient self-testing applications. Professional use and patient self-testing applications are viewed slightly
differently by the different regulatory bodies, but we’re well progressed in the discussions on that second
self-testing application.
In relation to sales, as of today, it’s a little bit too soon after launch to give any specific sales data but as far
as the UK is concerned, there is an important consideration to be taken into account when we look at this
market. And that’s regarding the government freely distributing, free of charge, lateral flow tests. We need to
get more of an understanding of when that will cease and what opportunities, therein, are available to us in
the UK. However, there remains significant opportunities in other non-NHS sectors in the UK, as well
as opportunities outside of the UK.
Our COVID-19 LFT portfolio also complements our existing task flow portfolio of lateral flow devices. And, as
well as COVID, we’ve now got an extensive portfolio of lateral flow devices which cover calprotectin,
adenovirus, streptococcus, as well as legionella.
Sign In
Follow the stocks
